[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100494707":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":18,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":18,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":39,"whyStopped":18,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Rabin Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tissue adhesive","EXPERIMENTAL","Tissue adhesive application at the CVL exit-site, on all CVLs, PICCs during the patient LOS. Regular CLABSI preventive protocol. Regular preventive CVL dressings (Chlorhexidine \\>2mo).",[13],"Device: 2-octyl cyanoacrylate based topical skin adhesive",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Regular CLABSI preventive protocol. Regular preventive CVL dressings (Chlorhexidine \\>2mo).",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DEVICE","2-octyl cyanoacrylate based topical skin adhesive","Tissue adhesive on CVL exit-site",[9],[26],{"name":27,"affiliation":28,"role":29},"Ovadia Dagan, Prof. M.D","Director PCICU, Schneider Children's Medical Center","STUDY_DIRECTOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},"Eran Shostak, MD","CONTACT","972-3-9253114","eransho@clalit.org.il",[37],{"facility":38,"status":39,"city":40,"state":18,"zip":18,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Schneider's children medical center","RECRUITING","Petah Tikva","Israel","IL",{"type":44,"coordinates":45},"Point",[46,47],34.88747,32.08707,{"lat":47,"lon":46},[50,51],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},{"name":52,"role":53,"phone":18,"phoneExt":18,"email":18},"Ofer Schiller, M.D","SUB_INVESTIGATOR",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","ERAN SHOSTAK","Principal Investigator","100494707","clabsi-prevention-with-tissue-adhesive-100494707",false,"NCT05721677","CLABSI Prevention With Tissue Adhesive","The Impact of Central-line Exit-site Sealing With 2-octyl Cyanoacrylate Adhesive on CLABSI in Pediatric Cardiac Intensive Care Unit","Cya-No-CLABSI","Inclusion Criteria:\n\nAll patients admitted to pediatric cardiac ICU (PCICU) defined as high-risk for CLABSI (any of):\n\n* young age\\\u003C1y \\& Congenital Heart Surgery Mortality Category (STAT\\\\STS-EACTS) score 2-5\n* Risk Adjustment for Congenital Heart Surgery (RACHS) category ≥3\n* preoperative length-of-stay (LOS) \\>7 days\n* preoperative ventilator support\n* presence of a genetic abnormality\n* extracorporeal membrane oxygenation (ECMO) support\n\nExclusion Criteria:\n\n* Patients with on-going bacteremia\n* patients with pre-existing central-line or peripherally inserted central catheter (PICC)\n* parental refusal to participate.","ALL","0 Days","18 Years",{"count":70,"type":71},600,"ESTIMATED","INTERVENTIONAL",[74],"NA","Our aim is to test the effect of tissue adhesive application at the Central-line exit-site on CLABSI rates in high-risk pediatric congenital heart disease patients.",[77],"Central-line Associated Blood Stream Infections (CLABSI)",[79,80,81,82,83],"CLABSI","Pediatric","Cardiac intensive care","cyanoacrylate","tissue adhesive","2024-09-30",{"date":86,"type":87},"2024-10-02","ACTUAL",{"date":89,"type":87},"2023-03-15",{"date":91,"type":71},"2026-09-15",{"name":5,"class":6},1]